Vascular effects of the lercanidipine/enalapril combination: clinical relevance

Research output: Contribution to journalComment/debate

Abstract

Hypertension is associated with alterations in the vascular structure, which in turn enhance the risk of cardiovascular events. Notably, anti-hypertensive treatment may prevent or regress the changes of arterial wall structures. Lercanidipine is a third-generation CCB with peculiar pharmaceutical properties. Enalapril is an effective drug acting on the renin–angiotensin–aldosterone axis. This commentary discusses the vascular effects of the lercanidipine/enalapril combination, and comments on their potential clinical relevance.

Original languageEnglish
Pages (from-to)25-28
Number of pages4
JournalCurrent Medical Research and Opinion
Volume32
DOIs
Publication statusPublished - Sep 30 2016

Fingerprint

Enalapril
Blood Vessels
Pharmaceutical Preparations
Antihypertensive Agents
Hypertension
lercanidipine

Keywords

  • Hypertension
  • Lercanidipine
  • Microcirculation
  • Stiffness
  • Vascular effects

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vascular effects of the lercanidipine/enalapril combination : clinical relevance. / Parati, Gianfranco.

In: Current Medical Research and Opinion, Vol. 32, 30.09.2016, p. 25-28.

Research output: Contribution to journalComment/debate

@article{4137b14a15af46e3b011f39b5ba3fbd8,
title = "Vascular effects of the lercanidipine/enalapril combination: clinical relevance",
abstract = "Hypertension is associated with alterations in the vascular structure, which in turn enhance the risk of cardiovascular events. Notably, anti-hypertensive treatment may prevent or regress the changes of arterial wall structures. Lercanidipine is a third-generation CCB with peculiar pharmaceutical properties. Enalapril is an effective drug acting on the renin–angiotensin–aldosterone axis. This commentary discusses the vascular effects of the lercanidipine/enalapril combination, and comments on their potential clinical relevance.",
keywords = "Hypertension, Lercanidipine, Microcirculation, Stiffness, Vascular effects",
author = "Gianfranco Parati",
year = "2016",
month = "9",
day = "30",
doi = "10.1080/03007995.2016.1218837",
language = "English",
volume = "32",
pages = "25--28",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Vascular effects of the lercanidipine/enalapril combination

T2 - clinical relevance

AU - Parati, Gianfranco

PY - 2016/9/30

Y1 - 2016/9/30

N2 - Hypertension is associated with alterations in the vascular structure, which in turn enhance the risk of cardiovascular events. Notably, anti-hypertensive treatment may prevent or regress the changes of arterial wall structures. Lercanidipine is a third-generation CCB with peculiar pharmaceutical properties. Enalapril is an effective drug acting on the renin–angiotensin–aldosterone axis. This commentary discusses the vascular effects of the lercanidipine/enalapril combination, and comments on their potential clinical relevance.

AB - Hypertension is associated with alterations in the vascular structure, which in turn enhance the risk of cardiovascular events. Notably, anti-hypertensive treatment may prevent or regress the changes of arterial wall structures. Lercanidipine is a third-generation CCB with peculiar pharmaceutical properties. Enalapril is an effective drug acting on the renin–angiotensin–aldosterone axis. This commentary discusses the vascular effects of the lercanidipine/enalapril combination, and comments on their potential clinical relevance.

KW - Hypertension

KW - Lercanidipine

KW - Microcirculation

KW - Stiffness

KW - Vascular effects

UR - http://www.scopus.com/inward/record.url?scp=84992453059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992453059&partnerID=8YFLogxK

U2 - 10.1080/03007995.2016.1218837

DO - 10.1080/03007995.2016.1218837

M3 - Comment/debate

AN - SCOPUS:84992453059

VL - 32

SP - 25

EP - 28

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

ER -